Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Rating of “Reduce” by Brokerages

Bausch Health Cos Inc. (NYSE:BHC) has received an average recommendation of “Reduce” from the seven research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.00.

A number of analysts have weighed in on the company. Zacks Research upgraded Bausch Health Cos from a “strong sell” rating to a “hold” rating in a research note on Thursday. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Weiss Ratings upgraded shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Royal Bank Of Canada dropped their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Finally, Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st.

Bausch Health Cos Trading Down 0.3%

NYSE BHC opened at $6.42 on Monday. Bausch Health Cos has a 52 week low of $4.33 and a 52 week high of $8.00. The firm has a 50 day moving average of $5.36 and a two-hundred day moving average of $5.46. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 54.68. The stock has a market capitalization of $2.40 billion, a PE ratio of -2.17 and a beta of 0.38.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.30. The business had revenue of $2.83 billion during the quarter, compared to analysts’ expectations of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. As a group, research analysts expect that Bausch Health Cos will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Aimee J. Lenar sold 36,827 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the sale, the insider directly owned 334,853 shares of the company’s stock, valued at $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by corporate insiders.

Institutional Trading of Bausch Health Cos

Several institutional investors and hedge funds have recently made changes to their positions in BHC. Tacita Capital Inc acquired a new stake in shares of Bausch Health Cos in the 2nd quarter valued at about $29,000. Caption Management LLC lifted its stake in Bausch Health Cos by 101.1% in the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after buying an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after buying an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Bausch Health Cos by 6,661.2% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after acquiring an additional 5,329 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after acquiring an additional 3,106 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.